Oncology

News

combination of directions for booted feet, two arrows

J&J says Rybrevant combo has survival edge over Tagrisso

Rybrevant plus Lazcluze extended median OS by more than a year compared to Tagrisso in the MARIPOSA trial in treatment-naive, EGFR-mutated NSCLC.

News

GSK bags breakthrough status for bone cancer drug

GSK has claimed its second breakthrough designation from the FDA for B7-H3-targeted ADC, this time in osteosarcoma.

R&D

12 Questions with Peter Wickersham

Peter Wickersham is the Vice President and General Manager of Gilead Sciences UK & Ireland, and a leader in HIV treatment, liver disease, and oncology.

News

CARsgen gets a win for CAR-T in solid tumours

CARsgen Therapeutics' claudin 18.2-targeting autologous CAR-T therapy satri-cel has shown efficacy in gastric cancer, setting up a filing in China.

News

Hutchmed cashes in a Chinese JV to help fund its pipeline

Hutchmed has agreed to divest its share of a non-core Chinese JV through a pair of deals that will give it a cash injection to plough into R&D.

News

Roche licenses Innovent ADC that could challenge Amgen drug

Roche licenses rights to a DLL3-targeted ADC from China's Innovent, hoping to bring a competitor to Amgen's lung cancer therapy Imdelltra to market.

J&J says Rybrevant combo has survival edge over Tagrisso

GSK bags breakthrough status for bone cancer drug

12 Questions with Peter Wickersham

CARsgen gets a win for CAR-T in solid tumours

Hutchmed cashes in a Chinese JV to help fund its pipeline

Roche licenses Innovent ADC that could challenge Amgen drug

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

Oncology

Editor's Picks